Although the BRAF-600E mutation is not present in all cases of histiocytosis, the alteration of the BRAF-MEK-ERK axis is universal; BRAF and MEK inhibitors such as dabrafenib and trametinib have recently been investigated for the treatment of patients with high risk or multiorgan damage, with favorable results, although more studies are still necessary to determine its long-term response [20]. The gene discussed is MAP2K7; the disease is Histiocytosis.